CJC-1295 + Ipamorelin + Tesamorelin
The CJC-1295 (no DAC) + Ipamorelin + Tesamorelin blend — sometimes abbreviated 'CIT' on certificates — is a research combination of three growth-hormone secretagogues that stimulate endogenous GH release through two complementary pituitary pathways (GHRH and the ghrelin receptor); research protocols typically inject the blend once nightly subcutaneously while fasted, dosed to the Tesamorelin content of about 1 mg to start (titrating toward ~2 mg), with the microgram-scale CJC-1295 and Ipamorelin riding along in the same vial.
Adults exploring, in a research context, endogenous growth-hormone and IGF-1 support for body-composition and visceral-fat interest. Because it stacks three active GH-axis peptides, it is not a sensible first peptide — physician guidance is strongly advised, and anyone with the GH-pathway contraindications below should avoid it.
This blend combines three synthetic growth-hormone secretagogues that raise GH through complementary mechanisms rather than delivering GH directly. Tesamorelin is a stabilized 44-amino-acid analog of growth-hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoic-acid modification that extends its half-life well beyond endogenous GHRH's ~7-minute window; it is FDA-approved (as Egrifta) for HIV-associated lipodystrophy and is the most clinically validated component, driving 15–20% reductions in visceral-fat area over 26 weeks in its pivotal trials by preferentially mobilizing deep abdominal fat. CJC-1295 (no DAC), also called modified GRF (1-29), is a synthetic analog of the first 29 residues of GHRH that binds the same GHRH receptor on pituitary somatotrophs, raising intracellular cAMP; its short half-life is chosen to approximate natural pulsatile release.
Ipamorelin is a selective pentapeptide agonist of the ghrelin / growth-hormone-secretagogue receptor (GHSR-1a) — a distinct receptor from GHRH — and is prized for stimulating a clean GH pulse without the cortisol, ACTH, or prolactin elevations seen with older GHRPs. Pairing a GHRH-pathway agonist with a ghrelin-receptor agonist is studied as a way to amplify total GH output through two independent receptors, while the Tesamorelin component adds a longer, visceral-fat-directed GHRH signal. Of the three, only Tesamorelin is FDA-approved; CJC-1295 (no DAC) and Ipamorelin are handled as research compounds, and controlled human data on the specific three-way combination are lacking.
Reconstitute the multi-peptide vial with about 2 mL bacteriostatic water and inject subcutaneously once nightly at bedtime. Because Tesamorelin is the milligram-scale component, the whole blend is anchored to its dose: start around 1 mg (Tesamorelin) nightly and titrate toward ~2 mg over several weeks; the microgram-scale CJC-1295 (no DAC) and Ipamorelin are premixed in fixed proportion and dose up alongside it. Inject fasted — no food for ~2 hours before and shortly after — so an insulin/glucose spike does not blunt the GH pulse. Bedtime timing aligns the pulse with the natural overnight GH surge.
Plasma GH typically rises within roughly 30–60 minutes of injection (the GHRH/ghrelin pulse). Downstream IGF-1 changes are studied over days to weeks, and Tesamorelin's visceral-fat effects are measured on imaging over roughly 12–24 weeks of consistent nightly use.
This is already a complete three-way GH-axis stack (GHRH analog + short GHRH analog + ghrelin-receptor agonist), so adding further GH secretagogues is usually redundant and stacks side-effect risk. It is generally run standalone.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.